Brentan (Miconazole): Main Uses

Quick Facts

• Therapeutic Domain: Assists in the management of fungal infections.
• Primary Uses: Used to address fungal infections affecting the skin, mouth, or vagina.
• Specific Conditions: Applied in the context of candidiasis, tinea cruris (jock itch), and tinea pedis (athlete's foot).

Brentan, containing the active ingredient miconazole, is utilized in the care of certain superficial fungal infections. The purpose of this medication is to help resolve the underlying fungal presence contributing to discomfort and symptoms. It is frequently indicated for conditions caused by Candida species and other fungi, which may manifest as infections of the skin or mucous membranes.

In the area of topical and mucosal care, the medication is part of a regimen to manage conditions such as vaginal candidiasis (yeast infection) and certain skin infections, including ringworm (tinea corporis) and athlete’s foot (tinea pedis).

Eligibility Map: Who can and cannot use Brentan — Official Regulatory Information

Eligibility Scope	Statement from Regulatory Labeling
Populations for whom use is allowed (as stated in label)	Adults and Adolescents (generally 12 years and older) for topical and vaginal use. Children aged 2 years and older for most topical applications.
Populations for whom use is not recommended (if applicable)	Children under 2 years of age for over-the-counter (OTC) topical use, unless specifically directed by a healthcare professional. Pregnant women in the first trimester should consult a doctor before use.
Populations for whom use is contraindicated	Individuals with known Hypersensitivity or allergy to the active substance Miconazole, other imidazole derivatives, or any of the product's excipients.
Age-related eligibility rules	Use in children under 12 years (vaginal) and infants less than four weeks of age is generally Not Established or requires physician consultation.
Condition-specific eligibility rules	No specific restrictions are documented for patients with hepatic or renal impairment for topical/vaginal formulations.
Pregnancy and lactation eligibility status (if explicitly documented)	Use during Pregnancy and Lactation requires consultation with a health professional due to the need to weigh benefits and risks.
Eligibility-related restrictions	Use of vaginal formulations is Not Recommended concurrently with latex barrier contraceptives (e.g., condoms, diaphragms), as the medication may compromise their integrity. Caution is required if the patient is taking warfarin, due to potential systemic interaction.

---

Eligibility Classifications (High-Level)

Eligibility severity classification (as defined in official documents)	Hypersensitivity is an Absolute Contraindication; Use under 2 years is classified as Do Not Use (OTC) or Not Established (Prescription).
Regulatory basis	FDA Prescribing Information, EMA SmPC, and National Health Authority Monographs.
Eligibility-context constraints (as defined in official documents)	Age, Allergic History, and Concomitant Product Use (Barrier Contraceptives, Warfarin).

---

Resulting Eligibility Structure

Official eligibility statements:

• The primary exclusion criterion is known hypersensitivity to the drug or related compounds.
• Eligibility for topical use begins at age two; use below this age is strongly restricted.
• Conditional restrictions apply to pregnant women and to patients on specific oral anticoagulants, necessitating medical review.

Connection to the overall eligibility profile (2–4 sentences): The regulatory documents define who can and cannot use Brentan by prioritizing absolute exclusion based on allergic history and imposing conditional restrictions related to age and reproductive status. Due to the drug's localized application, restrictions concerning systemic conditions like renal or hepatic impairment are generally absent from the official labeling.

Interactions with other medicines and products

This product, containing miconazole, has the potential to interact with a significant number of other medicines due to its documented ability to inhibit specific liver enzymes, primarily Cytochrome P450 3A4 (CYP3A4) and 2C9 (CYP2C9). The inhibition of these enzymes can lead to increased plasma concentrations of co-administered drugs that are metabolized by these pathways.

---

Key Interacting Medicinal Products and Classes

The regulatory profile identifies several drug categories where concurrent use requires special precautions or dose adjustments, or is restricted:

• Oral Anticoagulants (Blood Thinners): Co-administration, even with local formulations, can significantly enhance the effect of anticoagulants like warfarin. This combination carries a risk of increased bleeding and necessitates close, mandatory monitoring of blood clotting tests (e.g., INR).
• Sulfonylureas: The simultaneous use of this product with antidiabetic medicines in the sulfonylurea class may lead to an enhanced blood sugar-lowering effect.
• Specific Substrates for CYP3A4 and CYP2C9: This includes several medicines with narrow therapeutic windows, such as certain statins (HMG-CoA Reductase Inhibitors), certain anticonvulsants (e.g., phenytoin), and some anxiolytics (e.g., oral midazolam). Increased exposure to these drugs may occur.
• Vinca Alkaloids and Busulfan: The combination with certain anti-neoplastic agents, such as Busulfan, is considered a high-risk interaction, often requiring avoidance due to significantly increased toxicity risk.

Regulatory documents emphasize that the clinical relevance of these interactions is due to systemic absorption of miconazole, regardless of the route of administration, and that monitoring is critical for affected co-administered therapies.

Targeted Inhibition of the Ergosterol Biosynthesis Pathway

This mechanism begins at the molecular level by the drug acting as a non-competitive inhibitor of the fungal enzyme Lanosterol 14alpha-demethylase (CYP51). This specific inhibition blocks a critical step in the ergosterol biosynthesis pathway, preventing the fungus from synthesizing ergosterol, a sterol critical for fungal cell membrane structure. The consequence is the immediate disruption of the fungal cell's primary metabolic assembly line.

---

Compromising Fungal Cell Membrane Structure

The cessation of ergosterol synthesis, combined with the accumulation of toxic precursor compounds (C14-methylated sterols), damages the fungal cell structure. These abnormal sterols are incorporated into the membrane, increasing its fluidity and permeability, leading to the failure of integral membrane enzymes. This dual assault causes the uncontrolled leakage of essential intracellular contents and, ultimately, results in fungal cell lysis and irreversible damage, leading to the irreversible breakdown of the fungal cells.

Brentan, containing Miconazole Nitrate, is administered via topical (cutaneous) or intravaginal routes, using formulations such as creams, powders, and suppositories. The appropriate dosing regimen is defined by the form and the area of application.

Administration Routes and Standard Dosing

For cutaneous applications, a thin layer of the cream or powder is typically applied to the affected area twice daily. Treatment duration for skin infections, such as those caused by tinea, is generally a course ranging from 2 to 6 weeks. Standard practice involves continuing application for at least one full week after all signs have resolved to prevent relapse.

For intravaginal use, standard regimens include inserting a 200 mg suppository or one applicatorful of 4% cream once daily at bedtime for a 3-day course, or using the 100 mg/2% dose for a 7-day course. The instruction to administer at bedtime is to maximize contact time at the site of infection.

Contextual and Population Instructions

Before topical use, the affected skin must be washed and thoroughly dried to ensure proper adherence. The medicine is not for oral consumption. In terms of population-specific rules, the topical form is generally intended for use in patients ≥ 2 years of age, while the intravaginal forms are reserved for those ≥ 12 years of age. If a regular dose is missed, it is typically taken as soon as remembered; however, if it is nearly time for the next scheduled dose, the missed dose is skipped to prevent a double application.

Research Evidence / Overview of Studies for Brentan (Miconazole Nitrate)

---

Evidence for Use in Vulvovaginal Candidiasis

The foundation for understanding Brentan’s use in vaginal yeast infections relies primarily on Randomized Controlled Trials (RCTs). These studies were used in research exploring outcomes related to physical discomfort and the presence of the fungus change over defined time intervals. The core endpoints examined included the Therapeutic Cure Rate, a combined measure of both the patient's symptoms and the elimination of the fungus (Mycological Eradication).

Studies conducted during periods of increased symptom activity reported high measurements for the combined primary endpoint following various short-term treatment regimens (e.g., 3-day or 7-day courses). The evidence derived from over-the-counter (OTC) settings also shows patterns related to consumer-reported symptom resolution. However, the long-term effects are not fully established regarding how often the infection recurs, as follow-up durations were often limited to the immediate post-treatment period.

---

Evidence for Use in Superficial Skin Infections (Dermatophytoses and Cutaneous Candidiasis)

Brentan was studied for its use in superficial skin infections, including ringworm and skin candidiasis. The research largely comprises clinical efficacy trials which evaluated the topical product in settings where symptoms may vary in intensity. The core measurements involved looking for Clinical and Mycological Clearing, meaning the physical signs of the infection were resolved and lab tests no longer detected the fungus.

Research has explored how symptoms evolved in the observed populations, which included adults and children. Findings indicate that the medication was associated with the patterns of clearing and resolution measured during the specified treatment period. A limitation noted is that long-term outcomes are not well characterized for the long-term symptom patterns after the treatment period is finished. Comparative evidence against all alternative antifungal agents is lacking or remains limited.

---

Research Gaps and Areas of Uncertainty

A central limitation across the evidence base is that the follow-up durations were limited in many key trials, meaning the long-term patterns of infection recurrence are not fully established. Additionally, the research applies to conditions characterized by fluctuating or episodic manifestations, yet most studies focus on a single, acute episode. Data for certain groups, such as older adults with complex comorbidities or those with specific immune deficiencies, remain insufficient and were not the focus of the core registration trials.

Key Studies & References

1. Efficacy of antifungal drugs in the treatment of vulvovaginal candidiasis: a Bayesian network meta-analysis

Common questions about Brentan (FAQ)

---

Q: If I miss a dose of Brentan, what is the generally advised procedure?

Regulatory consumer information advises that if a missed dose is remembered, the general guidance advises applying it as soon as possible. However, if it is almost time for the next scheduled application, the missed dose should be skipped entirely. This guidance aims to prevent a double application of the medication.

---

Q: Are there any known issues with drinking alcohol while using Brentan?

Official drug documents focus on interactions between Brentan and specific oral medications, as the systemic absorption is generally low. A specific warning or restriction regarding the consumption of alcohol is not commonly noted on the topical or vaginal product labels.

---

Q: Does Brentan interact with common vitamins or herbal supplements?

Brentan (Miconazole) has the potential to interact with certain oral medications due to its effect on liver enzymes. Because it is not possible to definitively state the safety for all vitamins or supplements, official guidance emphasizes the importance of a healthcare provider being aware of all products being used, including vitamins and herbal supplements.

---

Q: Is it possible to have an allergic reaction to Brentan?

Yes, official safety documents indicate that allergic reactions are possible, although they are generally rare. The medicine is formally contraindicated, meaning it should not be used, if a person has a known allergy or hypersensitivity to the drug or related compounds. A severe allergic reaction is an event that requires immediate medical attention.

---

Q: Can Brentan be safely used during breastfeeding, according to official guidance?

Regulatory documents note that professional consultation is advised for nursing mothers. Due to the limited absorption from the skin and vagina, exposure to a breastfed infant is considered limited, but the benefit-risk assessment must be reviewed by a professional.

---

Q: Are there any common over-the-counter pain relievers that should not be taken with Brentan?

The regulatory warnings for Brentan are primarily focused on interactions with prescription drugs, specifically blood thinners and certain antidiabetic medicines. While specific warnings for common non-prescription pain relievers are not usually listed, a consultation with a healthcare provider is noted as important for any combination of medicines.

---

Q: Are there specific symptoms that mean a person should stop taking Brentan immediately?

Official safety documents indicate that events such as signs of a severe allergic reaction are those for which stopping use and seeking medical help immediately is generally advised. These may include difficulty breathing, significant swelling of the face or throat, or a severe, widespread rash or hives.

---

Q: Is Brentan safe to use for people who have diabetes?

Official labeling notes a potential drug-drug interaction with a class of oral antidiabetic medicines called sulfonylureas. This combination may enhance the blood sugar-lowering effect, and the combination may necessitate monitoring. General use for individuals with diabetes is not otherwise restricted.

---

Q: Can a person become reliant on Brentan over time?

Regulatory documents, which outline the safety profile and uses of the medicine, do not classify this antifungal medication as having any potential for physical dependence, abuse, or reliance.

---

Q: If Brentan is stopped, is there any possibility of withdrawal effects?

The official product information for this topical and vaginal antifungal medicine does not list any withdrawal effects associated with stopping its use.

---

Q: Does the time of day matter when taking Brentan?

For the intravaginal forms, official guidance often specifies application at bedtime to maximize contact time and effectiveness. For topical applications, the instruction is simply to apply twice daily, with no specific time of day mandated in the official instructions.

---

Q: Is it true that Brentan can affect birth control effectiveness?

Yes, official labeling states that the base material used in the vaginal forms of Brentan may damage latex contraceptive products, such as condoms or diaphragms. Regulatory notes indicate this damage could affect the intended barrier function.

---

Q: Is Brentan generally considered a short-term or a long-term treatment?

Official dosing regimens define Brentan as a short-term treatment. The course of application is typically finite, ranging from as little as 3 days up to 6 weeks, depending on the specific type and location of the infection being addressed.

---

Q: Is there a link between Brentan use and sun sensitivity?

The official side effect profile for Brentan, which includes common and uncommon reactions, does not list sun sensitivity (photosensitivity) as a commonly documented reaction.

---

Q: What happens if Brentan is taken in a much higher quantity than intended?

Topical ingestion is unlikely to cause serious systemic harm. However, in the event of accidental oral ingestion or overuse, contacting a poison control center immediately is the generally advised course of action, and seeking medical attention is necessary.

---

Q: Why is Brentan only available by prescription?

Miconazole Nitrate, the active ingredient in Brentan, is available in both over-the-counter (OTC) and prescription forms. The prescription status is typically reserved for products with higher strengths or specific combination formulations that require oversight from a healthcare professional.

---

Q: Why does Brentan sometimes cause digestive upset?

Digestive upset, such as nausea or diarrhea, is not listed as a common direct side effect of the topical or vaginal forms. However, if the medication is accidentally swallowed, or if some systemic absorption occurs, gastrointestinal distress may potentially result.

---

Q: Are there different strengths of Brentan available?

Yes, Brentan (Miconazole Nitrate) is available in different strengths for its various uses. This includes the 2% concentration for topical cream or powder and different dosages, such as 100 mg or 200 mg suppositories, for intravaginal use.

---

Q: Are there any official warnings about taking Brentan with grapefruit?

Official warnings about interactions are primarily focused on specific oral medications metabolized by certain liver enzymes. While grapefruit is known to inhibit these enzymes, it is not specifically cited on the topical or vaginal labels. Consultation with a healthcare provider is relevant regarding its use alongside any medication that is absorbed systemically.

How to Store and Dispose of Brentan (Miconazole Nitrate)

The official labeling mandates specific conditions to ensure the stability and safety of Brentan formulations.

Storage Requirements

The medication must be stored at Controlled Room Temperature, typically between 20°C and 25°C (68°F and 77°F). It must be kept in its original container, which should remain tightly closed. The product must be protected from excess heat and moisture; it is also specified that the product must not be frozen.

Disposal and Child Safety

Brentan must be stored out of the sight and reach of children to prevent accidental exposure. Disposal of unused or expired medication must follow local regulations. The preferred method is using a medication take-back program. If this is unavailable, the medication should be placed in the household trash after mixing it with an undesirable substance, and it must not be flushed down the toilet.